Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Board Changes

1 Jul 2020 07:00

RNS Number : 6223R
Ideagen PLC
01 July 2020
 

July 1st 2020

 

 

Ideagen PLC

("Ideagen" "the Company" or "the Group")

 

Board Change

 

Ideagen PLC (AIM: IDEA), a leading supplier of integrated risk management software to highly regulated industries, is pleased to confirm that Emma Hayes has today joined the Group as Chief Financial Officer, succeeding Graeme Spenceley, as announced on 7th January 2020.

 

Graeme has retired as a Director but will remain with the Group as Company Secretary and financial advisor to the Board. This role will be on a full-time basis until 31 October 2020 which will provide for a full and effective handover to Emma, and thereafter he will continue in that capacity on a part-time basis.

 

Emma was previously Group Finance Director, Capital Delivery and Commercial, at Severn Trent PLC having held the position since 2017. In this role she controlled a P&L and Balance Sheet of approximately ÂŁ600m and was responsible for driving operational efficiencies through her 100-strong team. Before that Emma spent 10 years with Deloitte LLP as a Corporate Finance Director where she led origination and execution of a wide range of M&A transactions. Emma qualified as a Chartered Accountant (ACA) with BDO.

Graeme Spenceley was previously awarded 750,000 share options under the Company's 2018 LTIP scheme (as announced on 29 March 2019 with details of the relevant scheme announced on 23 October 2018). The Board and Graeme have agreed that this award will be reduced to 187,500 options and that these will vest in full on the achievement of the first performance criteria (being the Company's share price reaching 196 pence over 30 consecutive business days).

Emma has in turn been awarded 562,500 share options under the 2018 LTIP with the same vesting conditions such that 187,500 of these options becoming eligible to vest on the first performance criterion described above being met, with the remainder becoming eligible to vest on the Company's share price reaching 259 pence over 30 consecutive business days. All other terms and conditions relating to the 2018 LTIP as previously described apply equally.

 

Ben Dorks, Chief Executive of Ideagen, commented; "Firstly, the Board would like thank Graeme for his outstanding commitment to Ideagen. His insight, acumen and support over the past 10 years has been invaluable and it has been a great pleasure to work alongside him. We are pleased that Graeme will remain with the business as Company Secretary which will provide for a robust transition.

 

The Board is delighted to welcome Emma to the Group who brings with her a deep understanding of both financial structures and processes and M&A. We will benefit hugely from Emma's experience and ability as Ideagen continues to execute its global growth strategy.''

 

There are no further disclosures to be made in relation to Emma Jane Hayes, aged 39, pursuant to Schedule 2(g) of the AIM Rules for Companies. .

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

 

Ben Dorks, Chief Executive Officer

 

Graeme Spenceley, Chief Financial Officer

 

 

 

 finnCap Limited

020 7220 0500

Henrik Persson/James Thompson/ Hannah Boros (Nomad)

 

Alice Lane (ECM)

 

 

Canaccord Genuity Limited

 020 7523 8000

Simon Bridges

 

Richard Andrews

 

 

 

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides IRM software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 4,700 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Emma Hayes

2.

Reason for the notification

a)

Position/status:

Chief Financial Officer

b)

Initial notification/Amendment:

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Ideagen plc

 

b)

LEI:

213800KS1MLITOVNYC85

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 0.1p

 

GB00B0CM0C50

b)

Nature of the transaction:

Grant of LTIPs over Ordinary Shares

c)

Price(s) and volume(s):

Price(s)

Volume(s)

n/a

562,500

 

d)

Aggregated information:

· Aggregated volume:

· Price:

See 4 (c) above

e)

Date of the transaction:

1 July 2020

 

f)

Place of the transaction:

Off market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFFFEIRLIIVII
Date   Source Headline
25th Jun 20147:00 amRNSAcquisition of EIBS Ltd
5th Jun 20142:06 pmRNSHolding(s) in Company
3rd Jun 20147:00 amRNSIssue of ordinary shares
16th May 20147:00 amRNSIssue of ordinary shares
7th May 20147:00 amRNSTrading Update and Further NHS Contract Wins
17th Mar 20147:00 amRNSNHS Contract Wins
4th Mar 20147:00 amRNSContract Wins and Trading Update
20th Jan 201411:54 amRNSHolding(s) in Company
14th Jan 20147:00 amRNSHalf Yearly Report
3rd Jan 20144:41 pmRNSSecond Price Monitoring Extn
3rd Jan 20144:35 pmRNSPrice Monitoring Extension
17th Dec 20137:00 amRNSNotice of Results
20th Nov 20137:00 amRNSAcquisition of Pentana Ltd
6th Nov 20137:00 amRNSTrading update
30th Oct 201312:22 pmRNSAnnual Report & Accounts
29th Oct 20132:38 pmRNSResult of AGM
16th Oct 201312:02 pmRNSHolding(s) in Company
8th Oct 20137:00 amRNSIssue of ordinary shares
7th Oct 20137:00 amRNSNotice of AGM
9th Sep 20137:00 amRNSFurther Healthcare Contract Wins
16th Jul 20137:01 amRNSFinal Results
16th Jul 20137:00 amRNSNew Contract Win worth £300k
9th Jul 20137:00 amRNSNotice of Results
3rd Jul 20137:00 amRNSAcquisition of MSS Management Systems Services Ltd
10th Jun 20137:00 amRNSStrategic Partnership
10th May 20131:15 pmRNSDirector/PDMR Shareholding
10th May 20137:00 amRNSVA Contract Update
7th May 20137:00 amRNSTrading Update
22nd Apr 20137:00 amRNSContract Wins and Trading Update
19th Mar 20132:39 pmRNSHolding(s) in Company
12th Mar 20137:00 amRNSContract Wins and Board Change
31st Jan 20137:00 amRNSIssue of Equity and Award of Options
22nd Jan 20137:00 amRNSHalf Yearly Report
16th Jan 20137:00 amRNSHealthcare Contract Wins and New Appointments
16th Jan 20137:00 amRNSHolding(s) in Company
10th Jan 20137:00 amRNSNotice of Results
7th Jan 201312:55 pmRNSResult of General Meeting and Issue of Equity
24th Dec 20121:07 pmRNSHolding(s) in Company
24th Dec 201212:21 pmRNSHolding(s) in Company
19th Dec 20123:00 pmRNSPosting of Circular and Notice of General Meeting
17th Dec 20127:00 amRNSPlacing and acquisition
29th Nov 20127:00 amRNSTrading Update
9th Nov 20124:16 pmRNSHolding(s) in Company
31st Oct 20121:40 pmRNSResult of AGM
10th Oct 20125:57 pmRNSHolding(s) in Company
8th Oct 201211:42 amRNSNotice of AGM and Change of Address
3rd Sep 20128:25 amRNSHolding(s) in Company
29th Aug 20127:00 amRNSHolding(s) in Company
29th Aug 20127:00 amRNSContract Win
24th Jul 20127:00 amRNSPreliminary Results 30 April 2012

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.